AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11576153
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg kg(‐1))
Trial: 16311460
Drug: New apparatus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New apparatus for performing infusion tests in a standardized and automated way
Trial: 2612300
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ALEC powder
Trial: 2612300
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 100 mg ALEC suspension
Trial: 2612300
Drug: ALEC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALEC treatment
Trial: 26244854
Drug: Telephone-delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered Cognitive Behavioral Therapy (CBT)
Trial: 23555980
Drug: Antimalarials only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarials only (intervention arm)
Trial: 23555980
Drug: Antimalarials only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarials only (control arm)
Trial: 16400044
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg Ca/d as calcium carbonate)
Trial: 11406341
Drug: Basal intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal intravenous infusion of saline solution with verbal instructions of a powerful painkiller (double-blind administration)
Trial: 8095149
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg noberastine
Trial: 8095149
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg noberastine
Trial: 18518727
Drug: Lumboventricular lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumboventricular lavage and simultaneous low-frequency head-motion therapy
Trial: 12784319
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg albendazole daily for 15 days
Trial: 26481918
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol at a dose of 2 mg/kg per day in three divided doses
Trial: 26481918
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen at a dose of 10 mg/kg 8-hourly and paracetamol at a dose of 16.2 mg/kg 8-hourly
Trial: 22687786
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg/day
Trial: 22507978
Drug: pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 20 mg/day
Trial: 19835669
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment for 12 weeks
Trial: 19835669
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug-free depressed patients)
Trial: 10366081
Drug: Citicoline (Neuroton,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (Neuroton, 1000 mg/day intramuscularly for 60 days)
Trial: 10366081
Drug: Placebo (physiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (physiologic solution with additives for 60 days)
Trial: 10366081
Drug: Citicoline (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (second 60-day treatment) in GC2 patients
Trial: 21173411
Drug: Blinded placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded placebo pills (indistinguishable from echinacea)
Trial: 15030841
Drug: Standard injection
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard injection method using Healon5
Trial: 11211574
Drug: Chyawanprash (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chyawanprash (15 g/d)
Trial: 29742699
Drug: Sham photobiomodulation
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham photobiomodulation in the sublingual region
Trial: 28421782
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no analgesic maneuver)
Trial: 24330893
Drug: Withania somnifera
RxNorm normalized name: WITHANIA SOMNIFERA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withania somnifera extract (WSE) 500 mg/d
Trial: 7589376
Drug: Nebulized L-ASA
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized L-ASA (90 mg.ml-1)
Trial: 7589376
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (glycine solution, 30 mg.ml-1)
Trial: 26920359
Drug: Neither marker
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither marker of CKD (eGFR ≥60 mL/min/1.73 m(2) and UACR <30 mg/g)
Trial: 24159258
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg once daily
Trial: 9671427
Drug: Betaxolol hydrochloride
RxNorm normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaxolol hydrochloride 0.25% (Betoptic S) administered to 17 POAG and 9 NTG eyes
Trial: 8024354
Drug: Nutropin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutropin (0.2 mg/kg/day)
Trial: 8024354
Drug: Protropin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protropin (0.2 mg/kg/day)
Trial: 2925041
Drug: Intravenous phenylalanine
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phenylalanine before treatment with carbidopa
Trial: 2925041
Drug: Carbidopa treatment
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbidopa treatment
Trial: 11752106
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg subcutaneous methylnaltrexone plus morphine
Trial: 11752106
Drug: Morphine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.05 mg/kg intravenously)
Trial: 8033514
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (240 kJ/h)
Trial: 2558404
Drug: Non-fractioned heparin
RxNorm normalized name: OMIDUBICEL NON-CULTURED FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fractioned heparin (NFH)
Trial: 4142795
Drug: Bleomycin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin 150 mg followed by radiation
Trial: 28302407
Drug: AS03-adjuvanted H7N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H7N1 vaccine (3.75μg or 7.5μg hemagglutinin with AS03A or AS03B)
Trial: 28302407
Drug: AS03-adjuvanted H7N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H7N1 vaccine
Trial: 21562746
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ZnSO(4) daily
Trial: 17084137
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) delivered by general practitioners (GPs)
Trial: 11335734
Drug: One 10-microg
RxNorm normalized name: sodium hyaluronate 10 MG/ML [Gel-One]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 10-microg dose
Trial: 11335734
Drug: One 5-microg
RxNorm normalized name: 5-chlorobenzoxazolin-2-one
DrugBank: Chlorzoxazone (DB00356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 5-microg dose
Trial: 11335734
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or three 5-microg doses
Trial: 11335734
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen of Recombivax HB
Trial: 11335734
Drug: Two 10-microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 10-microg doses
Trial: 8392285
Drug: AZQ at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZQ at 15 mg/day for 3 days i.v. every 4 weeks
Trial: 22664783
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg once-daily
Trial: 22664783
Drug: Warfarin (dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose-adjusted according to Japanese guidelines)
Trial: 20832925
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg caffeine
Trial: 11118463
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 75 mg/m² and Cisplatin (CDDP) 100 mg/m² for six cycles at 3-week intervals; 232 (81%) received all six cycles.
Trial: 9104519
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl plus im ketorolac (Group A)
Trial: 2822879
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg atenolol daily
Trial: 23184118
Drug: Gastrografin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (3 mL/kg diluted 1:3 with water)
Trial: 16821209
Drug: DHEA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA therapy (150 mg oral DHEA daily for 40 days)
Trial: 14581438
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium (90 mg) administered intravenously every 3 weeks for 27 weeks
Trial: 8728804
Drug: Psychological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological preparation (psychoprophylaxis)
Trial: 3137888
Drug: Tegafur 400
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur 400 mg/m2 and Tamoxifen 20 mg/daily (Group B)
Trial: 28716108
Drug: Physiotherapy, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy, 50 minutes per session, 4 weekly treatments
Trial: 25703777
Drug: TVPS‐3 Visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVPS‐3 Visual Sequential Memory, TVPS‐3 Visual Closure, and JTTHF dominant upper limb score
Trial: 4073304
Drug: Structured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured treatment (drug use exceeding set limits resulted in methadone withdrawal)
Trial: 4073304
Drug: Unstructured treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unstructured treatment (no consequences attended continued drug use)
Trial: 17516971
Drug: 1000 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 micrograms self-administered vaginal misoprostol
Trial: 18485172
Drug: Self-administered vaginal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered vaginal placebo
Trial: 15612099
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate tablets (18 mg to 54 mg/day in a single dose)
Trial: 15612099
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate capsules
Trial: 15612099
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate tablets
Trial: 10871573
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A (60 mg retinol equivalent)
Trial: 1327742
Drug: 55 g
RxNorm normalized name: NexoBrid 8.8 % Topical Gel, 55 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 55 g high-fibre oat bran
Trial: 1327742
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g mixed cooked beans
Trial: 21813065
Drug: sCD163 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCD163 at baseline (1.69mg/l (1.42‐2.10))
Trial: 12777644
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with ondansetron treatment
Trial: 12777644
Drug: Ondansetron treatment
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron treatment alone
Trial: 20562595
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg intravenous sotalol infusion administered over 2.5 hours
Trial: 2589359
Drug: Clindamycin-gentamicin combination
RxNorm normalized name: clindamycin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin-gentamicin combination
Trial: 2589359
Drug: Intravenous followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous followed by oral ciprofloxacin
Trial: 1099945
Drug: Ru-Tuss tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ru-Tuss tablets
Trial: 21161185
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hydrocortisone
Trial: 21535999
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hydrocortisone after learning
Trial: 9624373
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTA) injection (4 units total: 2 units in each nasal cavity for middle and inferior turbinate)
Trial: 3414581
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Zn/d
Trial: 3414581
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including vitamin-mineral supplement)
Trial: 26940805
Drug: ABT-126 25
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 25 mg
Trial: 28922590
Drug: ABT-126 75
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 75 mg
Trial: 19556043
Drug: Urine total
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine total protein level of 3.5 g/d or greater at baseline
Trial: 12397539
Drug: R-FCM (Rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-FCM (Rituximab + Fludarabine-Cyclophosphamide-Mitoxantrone); Rituximab 375 mg/m2 one day before FCM
Trial: 10211309
Drug: Retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate (300,000 I.U. daily for 1 month)
Trial: 2196145
Drug: Pentoxifylline 800
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 800 mg
Trial: 6129874
Drug: Clemastine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine (2 mg/day)
Trial: 17551300
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine 30 mg/m2 weekly
Trial: 17551300
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine for patients with KPS 60-70
Trial: 7594341
Drug: Lansoprazole (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (group L)
Trial: 2343792
Drug: Audiotaped administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Audiotaped administration of the Situational Competency Test (SCT)
Trial: 31337325
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (Referral to PTSD 'Standard Care')
Trial: 24007599
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity prescription + hyper‐corrective night‐time brace
Trial: 24007599
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity prescription + postural scoliosis‐specific exercises
Trial: 24007599
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity prescription (control group)
Trial: 21285388
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin aspart 70/30 BID (PIA)
Trial: 19002124
Drug: Late delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late delivery of stem cells via intramyocardial injection and intracoronary infusion (3-4 months after AMI)
Trial: 10212779
Drug: Ciprofloxacin (CPFX)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CPFX) 200 mg in a single oral dose (group A)
Trial: 10212779
Drug: Ciprofloxacin (CPFX)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CPFX) 200 mg once daily for 3 days (group B)
Trial: 10212779
Drug: Ciprofloxacin (CPFX)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CPFX) 200 mg twice daily for 3 days (group C)
Trial: 10212779
Drug: Cefpodoxime-proxcetil (CPDX-PR)
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime-proxcetil (CPDX-PR) 200 mg once daily for 3 days (group D)
Trial: 7786823
Drug: Early alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early alternating chemotherapy (ABABAB)
Trial: 7786823
Drug: Both early
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both early and late alternating chemotherapy
Trial: 7786823
Drug: Late alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late alternating chemotherapy (AAABBB)
Trial: 468745
Drug: Digit temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digit temperature biofeedback plus Rational-Emotive Therapy (RET)
Trial: 23033886
Drug: Selenium-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched yeast (100 μg daily for 3 months)
Trial: 3569766
Drug: Cisapride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (20 mg)
Trial: 10531162
Drug: Grepafloxacin (GFX)
RxNorm normalized name: GREPAFLOXACIN
DrugBank: Grepafloxacin (DB00365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Grepafloxacin (GFX) 600 mg qd
Trial: 10531162
Drug: Clarithromycin (CLA)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CLA) 500 mg bid
Trial: 29974545
Drug: Long cyberbullying
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long cyberbullying prevention program (10 weekly sessions)
Trial: 24760262
Drug: HLA type
RxNorm normalized name: HLA type C IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA type and number of positive antibodies
Trial: 22966077
Drug: Glucose feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose feeding (1 g/(kg·d) for 3 d)
Trial: 22966077
Drug: Fructose feeding
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose feeding (1 g/(kg·d) for 3 d)
Trial: 9135272
Drug: Hypotonic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic oral rehydration solution (ORS)
Trial: 1399929
Drug: High-dose ciprofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ciprofloxacin
Trial: 3160356
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Atenolol + Nitrendipine)
Trial: 21607780
Drug: i.v. paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. paracetamol 15 mg/kgBW
Trial: 21607780
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of i.v. ketoprofen and i.v. paracetamol
Trial: 21607780
Drug: Control (paracetamol)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (paracetamol)
Trial: 18281734
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of omeprazole
Trial: 18281734
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of omeprazole
Trial: 18281734
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of ritonavir with 800 mg of indinavir and 40 mg of omeprazole
Trial: 21296508
Drug: Extended-release zolpidem
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release zolpidem